https://pittplusme.org/study/1646
AURORA Study
This study is not currently recruiting. Please check back at a later time.
STUDY BASICS
Have you been diagnosed with nonalcoholic steatohepatitis (NASH) with suspected or diagnosed liver fibrosis? If so, you may be able to participate in a study to identify whether the study drug called cenicriviroc (CVC) is safe and effective for the treatment of scar tissue formation in the liver as a result of NASH. Involves multiple visits over 7-8 years, and will include up to 3 liver biopsies.
IRB: 20170037
- AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis
AGE:
18 - 75
DURATION:
7-8 years
VISITS:
Up to 35 visits
LOCATION:
UPMC Montefiore and UPMC Presbyterian
COMPENSATION:
$100 per visit ($50 for visit & $50 for travel)
SHARE STUDY
